Responses after one dose of a monovalent influenza A (H1N1) 2009 inactivated vaccine in Chinese population-A practical observation

Vaccine

Volumn 29, Issue 38, 2011, Pages 6527-6531

  Sun, Fuyan ^a   Zhang, Yunzhi ^a   Tian, Di ^a   Zheng, Min ^b,c   Liu, Li ^a   Zhang, Renfang ^a   Dai, Zhengsheng ^a   Chen, Jun ^a   Li, Tingting ^b   Lu, Hongzhou ^a,d,e  

^a SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^b West Lake Technology and Economy Park   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

2009 A H1N1 influenza vaccine; Immunogenicity; Safety

Indexed keywords

INACTIVATED VACCINE; INFLUENZA A (H1N1) VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY TITER; ARTICLE; BACKACHE; CLINICAL TRIAL; COMMON COLD; COUGHING; DEATH; DIARRHEA; DIZZINESS; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HEMATURIA; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE SWELLING; ISCHIALGIA; MAJOR CLINICAL STUDY; MYALGIA; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; THORAX DISEASE; VIRUS NEUTRALIZATION;

ADULT; ANTIBODIES, VIRAL; CHINA; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VACCINES, INACTIVATED;

EID: 80051667070     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.006     Document Type: Article

References (25)

1. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615.
2. Trifonov V., Khiabanian H., Rabadan R. Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus. N Engl J Med 2009, 361(2):115-119.
3. Peiris J.S., Poon L.L., Guan Y. Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009, 45(3):169-173.
4. Centers for Disease Control and Prevention (CDC) Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009, 58(17):467-470.
5. Influenza pandemic alert raised to phase 6 2009, World Health Organization, Geneva, Available from: http://www.un-influenza.org/node/3087.
6. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009, 58(19):521-524.
7. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952.
8. Garcia-Garcia L., Valdespino-Gomez J.L., Lazcano-Ponce E., Jimenez-Corona A., Higuera-Iglesias A., Cruz-Hervert P., et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 2009, 339:b3928. PMCID: 2758337.
9. World Health Organization (WHO). Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development, X-179A; May 2009. Available from: http://www.who.int/csr/resources/publications/swineflu/2009_05_27_X179Aa.pdf.
10. World Health Organization (WHO). Pandemic (H1N1) 2009 guidance documents. Available from: http://www.who.int/csr/resources/publications/swineflu/en/%23A.
11. Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009, 48(8):1087-1095.
12. Fang Y., Ye P.F., Wang X.B., Xu X., Reisen W. Real-time monitoring of flavivirus induced cytopathogenesis using cell electric impedance technology. J Virol Methods 2011, 173(2):251-258.
13. Di T, Zhang WJ, Li TT, Liu Y, Zhou ZT, Lu HZ, et al. Real-time monitoring of influenza virus-mediated cytopathogenicity and development of a novel neutralization assay for measurement of neutralizing antibody titers, in press.
14. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375(9708):56-66.
15. Food and Drug Administration Center for Biologics Evaluation and Research Office of Vaccines Research and Review. Regulatory considerations regarding the use of novel influenza A (H1N1) virus vaccines; July 23, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM172424.pdf.
16. The European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). London; 5 April, 2004.
17. National Institute of Allergy and Infectious Diseases. Division of Microbiology and Infectious Diseases (DMID) Adult Toxicity Tables. November 2007 DRAFT. Available from: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidadulttox.doc.
18. World Health Organization (WHO). CDC protocol of real time RT-PCR for influenza A (H1N1). Available from: http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf.
19. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413.
20. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
21. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(9708):41-48.
22. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
23. Rizzo C., Rota M.C., Bella A., Alfonsi V., Declich S., Caporali M.G., et al. Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine 2010, 28(20):3558-3562.
24. Boyd J.M., Huang L., Xie L., Moe B., Gabos S., Li X.F. A cell-microelectronic sensing technique for profiling cytotoxicity of chemicals. Anal Chim Acta 2008, 615(1):80-87.
25. Solly K., Wang X., Xu X., Strulovici B., Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2004, 2(4):363-372.